Business
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use
CLERMONT-FERRAND, France & TOKYO, Japan, May 04, 2026--Kubota Vision Inc. ("Kubota Vision"), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization.
About this update from Kubota Pharmaceutical Holdings Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":410,"url":"https://media.zenfs.com/en/business-wire.com/c1df0cac5f896949794ec4ad505348d9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VDZYILtsutQENKFZagM2qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTgyMA--/https://media.zenfs.com/en/business-wire.com/c1df0cac5f896949794ec4ad505348d9","width":480,"height":410}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":293,"url":"https://media.zenfs.com/en/business-wire.com/239ca0b509e7b114e1a168bece3675e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TMkIYWFuAhba9PZy331sHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4Ng--/https://media.zenfs.com/en/business-wire.com/239ca0b509e7b114e1a168bece3675e5","width":480,"height":293}}},{"type":"text","content":"CLERMONT-FERRAND, France & TOKYO, Japan, May 04, 2026--(BUSINESS WIRE)--Kubota Vision Inc. ("Kubota Vision"), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization.","length":430,"tagName":"p"},{"type":"text","content":"The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing "Emixustat" for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France.","length":202,"tagName":"p"},{"type":"text","content":"Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access.","length":186,"tagName":"p"},{"type":"text","content":"Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, "We are extremely pleased to enter into this Agreement with Laboratoires KÔL for the development, supply and distribution of Emixustat for Stargardt disease (STGD1). By combining Kubota Vision’s clinical development and visual cycle modulation technology with KÔL’s expertise in rare ocular diseases, we aim to d...